NCT02549911.

Trial name or title	Hyperthermic intraperitoneal chemotherapy, intravenous chemotherapy combined with surgery for the treatment of advanced gastric cancer with peritoneal metastasis
Methods	Phase 2 Intervention Model: Single‐group assignment Masking: Open‐label Primary Purpose: Treatment
Participants	N = 40 18‐75 years Gastric cancer confirmed by endoscopic biopsy , and enhanced CT suspected to have peritoneal metastasis, including ascites, ovarian metastasis, omentum or peritoneal metastasis.
Interventions	Experimental: HIPEC,Chemotherapy AND surgery Surgical exploration,if PCI < 20,then we perform this study HIPEC（RHL‐2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m² , twice, within 72 hours after surgical exploration ; oral chemotherapy:S‐1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80 mg/m², twice daily (after the breakfast and supper) for two weeks, and then suspend for one week. Chemotherapy (3 cycles) : Taxol 150 mg/m² ,d 1, S‐1: 80 mg/m², twice daily (after breakfast and supper) for two weeks, and then suspend for one week. Surgery: Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumours and metastases ) after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles Intervention: Other: HIPEC, chemotherapy AND surgery
Outcomes	R0 resection [Time frame: 3 months] Adverse events [Time frame: 6 months] Overall survival time [Time Frame: 3 years]
Starting date	September 2015
Contact information	Yian Du, MD; ypfzmu@163.com; 86‐571‐88128031
Notes